[Development of a novel disease modifying oral therapy for pulmonary arterial hypertension]- Leading SBIR phase II by establishing objectives, timelines, budgets, and managing CROs studies. - Monitoring project risks by identifying potential issues early and developing contingency plans. - Coordinating the review and submission of research protocols, ensuring regulatory compliance.

[Development of novel therapeutic in a preclinical model of kidney and lung disease progression]- Developed formulation for oral dose to determine the PK and PD profiles and in vivo efficacy. - Performed RNA-seq, qPCR, WB, ELISA analysis and validated mechanism of action.- Maintained equipment, drafted SOPs, documented experiments in adherence to guidelines. [Development of a novel therapeutic bio-device for renal recovery in hepatorenal syndrome patients]- Generated matrix-immobilized protein retaining full activity and incorporated into TED. - Characterized bioconjugate stability, enzymatic activity, and fluids compatibility.

[A novel transcriptional modulator as a disease modifying therapy for cardiometabolic disease]- Designed reporter assay for screening and completed SAR and lead optimization with chemists. - Generated and structured preliminary data for grant applications, securing >$1 million in funding.[Engineering a protein to optimize activity and extend in vivo half-life suitable for parenteral therapy]- Optimizing protein tagging and site-specific labeling improved protein stability and function.- Utilized VHH-based antibody-drug conjugate strategies, resulting in an extended in vivo half-life.

[Develop a novel long-acting protein and assess its activity as a bio-therapeutic molecule]- Cloning, expression, purification, and PEGylation of human and pseudomonas protein.- Performed chromatographic separation of metabolite stereoisomer using HPLC to evaluate efficacy.[Intratracheal delivery of liposomal cerivastatin as an approach for the treatment of PAH]- Generated the liposomal cerivastatin and evaluated encapsulation efficiency and release profile. - Inhaled liposomal cerivastatin demonstrated efficacious and safety profile with sustained release.[Formulation of ADMA-targeting enzyme for treatment of ischemic kidney injury]- Investigated protein bioconjugates, including lipidation, immobilization, coupling to liposomes.- Explored freeze-drying optimization for protein-loaded liposomal formulation for long-term stability.

[Drug formulation of lipid-based nanoparticles and targeted drug delivery to bladder tumor site]- Developed liposomal formulations encapsulating APIs, nucleic acids, and macromolecule complexes.- Fabricated liposomes with targeting peptide and evaluated intracellular trafficking and localization.